secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001104659-23-001705
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome partners with AbbVie for up to 10 novel oncology targets; $30M upfront
-------------------------------------------------------------------------------

- Immunome grants AbbVie options to purchase up to 10 novel antibody-target pairs from three tumor types.
- Upfront payment of $30M; potential platform access payments up to $70M based on research continuations.
- Development and first commercial sale milestones up to $120M per target; sales milestones and tiered royalties low single digits.
- Research term at least 66 months; exclusive to AbbVie for selected tumor types during term.
- Collaboration leverages Immunome's Discovery Engine; Immunome retains platform technology rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/0001104659-23-001705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/tm231749d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-001705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer